www.impactjournals.com/oncotarget/ Oncotarget, 2016, Vol. 7, (No. 51), pp: 84705-84717 Research Paper KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients Sarah Kammerer1,2, Armin Sokolowski1,9, Hubert Hackl3, Dieter Platzer1, Stephan Wenzel Jahn4, Amin El-Heliebi5, Daniela Schwarzenbacher6, Verena Stiegelbauer6, Martin Pichler6,7, Simin Rezania1,2, Heidelinde Fiegl8, Florentia Peintinger4, Peter Regitnig4, Gerald Hoefler4, Wolfgang Schreibmayer1,2, Thomas Bauernhofer2,6 1Molecular Physiology Group, Institute of Biophysics, Medical University of Graz, Austria 2Research Unit on Ion Channels and Cancer Biology, Medical University of Graz, Austria 3Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Austria 4Institute of Pathology, Medical University of Graz, Austria 5Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Austria 6Division of Oncology, Department of Internal Medicine, Medical University of Graz, Austria 7Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 8Department of Gynecology and Obstetrics, Medical University of Innsbruck, Austria 9Present address: Division of Prosthodontics, Restorative Dentistry, Periodontology and Implantology, Medical University of Graz, Austria Correspondence to: Thomas Bauernhofer, email:
[email protected] Keywords: KCNJ3, GIRK1, biomarker, estrogen receptor positive breast cancer, RNA in situ hybridization Received: June 04, 2016